Αρχική World News Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole COVID-19...

Vax-On Points to Maintenance of Active Anticancer Treatment Throughout the Whole COVID-19 Vaccination Schedule

In a large population of patients with solid tumours undergoing active anticancer treatment, the researchers confirmed a favourable safety profile of mRNA-BNT162b2 vaccine, which may reassure on maintaining active anticancer treatment throughout the whole vaccination schedule. Humoral response to first vaccine dose was inadequate, but the second, booster dose resulted in an exponential increase in IgG titre and high rate of seroconversion, arguing against delays in dosing schedule. Although some clinical features predict reduced immunogenicity, further investigation is required to confirm their significance. The findings from the Vax-On study are published online on 19 September 2021 in the Annals of Oncology by Dr. Fabrizio Nelli of the Department of Oncology and Haematology, Medical Oncology Unit, Central Hospital of Belcolle in Viterbo, Italy and colleagues.

In the Vax-On observational study, the study team assessed the effects of active anticancer treatment on safety and immunogenicity of mRNA-BNT162b2 vaccine in patients with solid tumours. They prospectively enrolled patients who started the 3-week apart mRNA-BNT162b2 vaccine schedule from 9 March to 12 April 2021 (timepoint 1). Those on active anticancer treatment within the previous 28 days accounted for the exposed cohort. Patients who had discontinued anticancer treatment by at least 28 days represented the control cohort. Safety analysis and quantification of anti-SARS-CoV-2 Spike IgG were performed before the second dose (timepoint 2) and 8 weeks thereafter (timepoint 3).

The titration was performed using the Abbott SARS-CoV-2 chemiluminescent microparticle immunoassay and seroconversion was defined at ≥50 AU/mL IgG titre. No SARS-CoV-2 rRT-PCR swab test or serologic titre was required at baseline. The study was approved by referring ethics committee and formally registered (EudraCT N.2021-002611-54).

The study team enrolled 366 patients of whom 285 in exposed cohort and 81 in the control cohort. The cohorts were mostly homogeneous. The adjuvant chemotherapy setting, prevalent in control cohort, accounts for the difference. Severe adverse events were rare, observed in just 1%. The most common adverse reactions were mild injection site reactions. Systemic adverse events did not exceed 17% of cases and were significantly associated with female sex, ECOG performance status 2 or G-CSF use.

At timepoint 2, the median IgG titre of 131 AU/ml (95% confidence interval [CI] 77-173) versus 62 AU/ml (95% CI 42-82) with p value of 0.029, median log IgG titre with p value of 0.033, and seroconversion rate of 65% versus 52% with p value of 0.048 were significantly higher in control cohort.

The median IgG titre, median log IgG titre, and percentage of seroconverted patients in control and exposed cohorts did not differ at timepoint 3. A significant 15-fold or greater increase in median IgG titres and seroconversion rates up to 91% were observed from timepoint 2 to 3 within the same cohorts (p < 0.001).

Multivariate analysis did not confirm a negative interaction between cytotoxic chemotherapy and antibody response, but ECOG performance status 2 and G-CSF use were significantly associated with lower IgG titre and lack of seroconversion after either dose of vaccine.

The authors concluded about a favourable safety profile of mRNA-BNT162b2 vaccine in patients with solid tumours during active anticancer treatment. They commented that patients with specific conditions, such as female sex and use of G-CSF, should be cautioned about increased risk of side effects. Although some clinical features predict reduced immunogenicity, further research is needed to confirm their significance.


Nelli F, Fabbri A, Onorato A, et al. Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: Preliminary results from the prospective observational Vax-On study. Annals of Oncology; Published online 19 September 2021. DOI: https://doi.org/10.1016/j.annonc.2021.09.009



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης

Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α

Εάν είστε καρκινοπαθής, το ανοσοποιητικό σας σύστημα μπορεί να μην είναι τόσο ισχυρό όσο κανονικά, έτσι μπορεί να ανησυχείτε για τους κινδύνους που σχετίζονται...


Η Παγκόσμια Ημέρα Κατά του Καρκίνου καθιερώθηκε με πρωτοβουλία της Διεθνούς Ένωσης κατά του Καρκίνου (UICC), που εκπροσωπεί 800 οργανώσεις σε 155 χώρες του...


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...
- Advertisment -

Ροή Ειδήσεων

Breast Cancer Survivor Invents Warming Bra Insert to Combat Cold Feeling of Breast Implants

In 2013, Kristen Carbone, of Providence, Rhode Island, had a preventative mastectomy to help protect herself against breast cancer after her mother died of...

FDA Approves Daratumumab plus Hyaluronidase-fihj, Carfilzomib, and Dexamethasone for Relapsed or Refractory Multiple Myeloma

On 30 November 2021, the US Food and Drug Administration (FDA) approved daratumumab plus hyaluronidase-fihj (Darzalex Faspro, Janssen Biotech, Inc.) and carfilzomib (Kyprolis, Amgen,...

Thanks For Making This GivingTuesday Our Best One Yet!

We set ambitious goals for GivingTuesday, but they were driven by a time of great need. With your help, we hoped to provide food and...

Over 600 people in England set to benefit from innovative lung cancer treatment

<img width="620" height="348" src="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg" class="attachment-featuredImage size-featuredImage" alt="Lung cancer cell" loading="lazy" srcset="https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero.jpg 620w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-300x168.jpg 300w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-220x123.jpg 220w, https://34p2k13bwwzx12bgy13rwq8p-wpengine.netdna-ssl.com/wp-content/uploads/2021/05/lung_cell_cropped-hero-150x84.jpg 150w" sizes="(max-width: 620px) 100vw, 620px" data-attachment-id="18781" data-permalink="https://news.cancerresearchuk.org/2020/09/11/targeted-drug-for-lung-cancer-approved-for-nhs-use-in-england/lung_cell_cropped-hero/"...

Touching a nerve: How neuroscience could advance our understanding of cancer

KTSDESIGN/SCIENCE PHOTO LIBRARY When supporters donate to our work, their combined generosity might lead to a new discovery that inches us closer to, for example,...

Nivolumab Demonstrates Clinical Benefits in a Statistically Evaluable Number of Patients with CUP

An investigator-initiated phase II study is the first to show that nivolumab has clinical activity with manageable toxicity in a statistically evaluable number of...